Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Conclusions
LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths.
Clinical Trial Registration
https://clinicaltrials.gov/, NCT01035255.
Source: European Heart Journal - Category: Cardiology Authors: Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., Gong, J., Rizkala, A. R., Brahimi, A., Claggett, B., Finn, P. V., Hartley, L. H., Liu, J., Lefkowitz, M., Shi, V., Zile, M. R., Solomon, S. D. Tags: Heart failure/cardiomyopathy Source Type: research
More News: Cardiology | Cardiomyopathy | Cardiovascular | Clinical Trials | Enalapril | Heart | Heart Attack | Heart Failure | Stroke